Promising Alzheimer's drugs offer hope for slowing cognitive decline.

Two new drugs for Alzheimer's disease have been approved by the US Food and Drug Administration, offering hope to patients after decades of waiting for effective treatments. The drugs, Aduhelm and Leqvio, work by targeting the buildup of amyloid protein in the brain, a hallmark of Alzheimer's. While some experts have raised concerns about the drugs' effectiveness and high cost, others see them as a significant step forward in the fight against the debilitating disease.